Therapeutic banner
Therapeutic banner

Transthyretin (ATTR) Amyloidosis

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Explore Therapeutic Areas

Congresses

View More Arrow
Congress-AHA-thumbnail Upcoming

Transthyretin Amyloidosis (ATTR)

American College of Cardiology (ACC) 2026

March 28-30, 2026 USA

View Details
Congress-ISPOR-Mobile

Transthyretin Amyloidosis (ATTR)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025

November 9-12, 2025 UK

View Details
Congress-AHA-thumbnail

Transthyretin Amyloidosis (ATTR)

American Heart Association (AHA) 2025

November 7-10, 2025 USA

View Details
Congress-HFSA-Mobile

Transthyretin Amyloidosis (ATTR)

Heart Failure Society of America (HFSA) 2025

September 26-29, 2025 USA

View Details
Congress-EU-ATTR-Mobile

Transthyretin Amyloidosis (ATTR)

European ATTR Amyloidosis Meeting (EU-ATTR) 2025

September 25-26, 2025 ITALY

View Details
Congress-CAPT-Mobile

Transthyretin Amyloidosis (ATTR)

Canadian Association for Population Therapeutics (CAPT) 2025

September 22-23, 2025 CANADA

View Details

Publications

View More Arrow

Transthyretin Amyloidosis (ATTR)

Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis

Journal of Clinical Medicine

Author(s)

Akash Singh, John Wyatt, Marie Théaudin, et al

September 2025

Transthyretin Amyloidosis (ATTR)

Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicenter Study

Annals of Medicine

Author(s)

Yessar Hussain, Saurabh Malhotra, Brett W. Sperry, et al

September 2025

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B

JACC: Advances

Author(s)

Ronald M. Witteles, Pablo Garcia-Pavia, Caroline Morbach, et al

August 2025

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial

Nature Medicine

Author(s)

Karola S. Jering, Marianna Fontana, Olivier Lairez, et al

August 2025

Transthyretin Amyloidosis (ATTR)

Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B

Journal of the American College of Cardiology

Author(s)

Mathew S. Maurer, John L. Berk, Thibaud Damy, et al

August 2025

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Journal of the American College of Cardiology

Author(s)

Karola S. Jering, Marianna Fontana, Hicham Skali, et al

August 2025